In two unrelated cases, the Office of Research Integrity (ORI) has sanctioned a grad student and a pair of colleagues, one of whom plagiarized and the other allowed the intellectual theft to go unchecked.
We think the handling of these cases — both first noted briefly by The Chronicle of Higher Education — is worth noting.
Continue reading ORI roundup: Former SUNY grad student, two Kansas U researchers hit with sanctions
Last week, we brought you the tale of a paper about camels that was rejected on submission, but published accidentally, and then retracted. It turns out this was not a unique occurrence.
An eagle-eyed Retraction Watch reader emailed us about another such paper, this one in the Journal of Nanoparticle Research. The study, “Growth of gold flowers on polyacrylonitrile fibers,” appears to have been published online on December 3, 2008. It now sports this retraction notice: Continue reading Another paper rejected, mistakenly published, then retracted, this one in nanotechnology journal
In the wake of the massive allegations of fraud by resveratrol researcher Dipak Das, other researchers in the field are clearly trying to distance themselves from the University of Connecticut scientist. Nir Barzilai told us yesterday, for example, that despite Das seemingly’ impressive publication record, “Rome was not built on Dr. Das.”
Harvard’s David Sinclair went further, telling The New York Times that he didn’t know who Das was: Continue reading So how peripheral was Dipak Das’ resveratrol work, really?
Many Retraction Watch readers will now be familiar with the case of Dipak Das, the resveratrol researcher about whom the University of Connecticut issued a voluminous report yesterday — summary here — detailing 145 counts of data fabrication and falsification. This has been a fast-moving story, so we wanted to highlight a number of updates to our original post, and offer a few more.
First, we have confirmed with publisher Mary Ann Liebert this morning that Das has been relieved of his duties as co-editor in chief of Antioxidants & Redox Signaling. He had shared that post with Chandan Sen, and his name as been removed from the masthead of that journal. Here’s a statement from the publisher: Continue reading Resveratrol fraud case update: Dipak Das loses editor’s chair, lawyer issues statement refuting all charges
The University of Connecticut, in what clearly seems like an attempt to get ahead of damaging news, has announced an “extensive” investigation into research misconduct involving one of its scientists, Dipak K. Das.
According to a press release, the university has notified 11 journals that published Das’ work about the alleged fraud. One area of interest for Das, a government-funded professor of surgery and director of the Cardiovascular Research Center, has been resveratrol, a substance in red wine that has allegedly been linked to improved cardiac health.
The university touted some of his early efforts in this field.
[Please also see our update posted Thursday.]
Here’s what the release has to say: Continue reading UConn resveratrol researcher Dipak Das fingered in sweeping misconduct case
If there’s one thing worse than having your paper rejected by a journal, it’s having it retracted. But usually a paper has to be accepted before it’s published and withdrawn.
Not so for a study from the United Arab Emirates, “Detection and genotyping of GB virus-C in dromedary camels in the United Arab Emirates,” published in 2010 in Veterinary Microbiology.
The editors of the journal ruminated — hey now! is this thing on? — on the paper, only to give it the thumbs down. But come to find out, it got published anyway. Thus, the following retraction notice, which appeared online last month: Continue reading Eye of the needle? Paper about camels gets rejected, then published, then retracted
What do you do when it turns out the materials you used in your successful experiment weren’t actually the materials you thought they were?
If you’re Peter Zammit, of King’s College London, and colleagues, you retract a 2008 paper in the Journal of Cell Science. Here’s the notice, for “B-catenin promotes self-renewal of skeletal-muscle satellite cells:” Continue reading Authors retract Journal of Cell Science study after realizing they were using the wrong gene constructs
The Journal of Clinical Oncology (JCO) has retracted a November 2011 editorial by a group of French cancer researchers, including David Khayat, the former head of that country’s National Cancer Institute, over what appears to be fairly extensive plagiarism.
Here’s the notice for the article, “Lymphocyte Infiltration in Breast Cancer: A Key Prognostic Factor That Should Not Be Ignored:” Continue reading JCO retracts article from major French cancer group over apparent plagiarism
Some retractions beg for a kick of sand in the face, and others do the kicking. Here’s an example of what Charles Atlas might have written had he been a journal editor concerned with research integrity.
Experimental Biology and Medicine, the official journal of the Society for Experimental Biology and Medicine, has retracted a 2010 article by a group of stem cell scientists in China with an unfortunate affinity for a particular figure—one they’d used in a previous publication, only with a different description.
Here’s the notice for the paper, “Isolation and characterization of multipotent progenitor cells from the human fetal aorta wall,” which was cited five times before it was retracted, according to Thomson Scientific’s Web of Knowledge: Continue reading Journal retracts heart stem cell paper (and pulls no punches) over image fraud
The journal Cancer has issued an Expression of Concern about two lung cancer screening papers long dogged by doubt.
Last April, The Cancer Letter and The New York Times jointly published an investigation into the International Early Lung Cancer Action Program (I-ELCAP) run by Claudia Henschke and David Yankelevitz. Other researchers had already criticized the design and conclusions of that trial, but as the investigation noted, an October 2008 review of the study found that the researchers couldn’t find 90 percent of the subjects’ consent forms, an ethical no-no that jeopardizes as many as 135 papers.
Two papers published in Cancer, in 2000 and 2001, are among those studies, according to the notice (links added), which credits the Times and The Cancer Letter and notes that the journal has referred the case to Federal investigators: Continue reading Cancer issues expression of concern about two Henschke I-ELCAP lung cancer screening papers
